https://www.selleckchem.com/products/MK-1775.html
Temporal lobe epilepsy is the most common form of epilepsy, and current antiepileptic drugs are ineffective in many patients. The endocannabinoid system has been associated with an on-demand protective response to seizures. Blocking endocannabinoid catabolism would elicit antiepileptic effects, devoid of psychotropic effects. We herein report the discovery of selective anandamide catabolic enzyme fatty acid amide hydrolase (FAAH) inhibitors with promising antiepileptic efficacy, starting from a further investigation of our prototypical

https://www.selleckchem.com/pr....oducts/tiragolumab-a
uary 2018; April 2019. Clinical Trial Registration (CTR) Number EUPAS23075. Trial Register Date March 12, 2018. First patient visit; Last patient visit February 2018; April 2019. Despite recent advances in the drug discovery field, developing selective kinase inhibitors remains a complicated issue for a number of reasons, one of which is that there are striking structural similarities in the ATP-binding pockets of kinases. To address this problem, we have designed a machine learning model utilizing various structure-based